礼来周一推出Zepbound多剂量KwikPen注射装置,患者仅需一支笔即可完成一个月四次给药,最低月价299美元,并已获FDA批准扩展标签。受此消息提振,礼来股价盘中涨超5%。与此同时,竞争对手诺和诺德的下一代减肥药CagriSema在头对头研究中未能达到“不劣于”Zepbound的主要目标,股价大跌16%。礼来周一推出了其重磅减肥药Zepbound的一种新剂型。新版本采用单支笔装,可提供一个月...
Source Link礼来周一推出Zepbound多剂量KwikPen注射装置,患者仅需一支笔即可完成一个月四次给药,最低月价299美元,并已获FDA批准扩展标签。受此消息提振,礼来股价盘中涨超5%。与此同时,竞争对手诺和诺德的下一代减肥药CagriSema在头对头研究中未能达到“不劣于”Zepbound的主要目标,股价大跌16%。礼来周一推出了其重磅减肥药Zepbound的一种新剂型。新版本采用单支笔装,可提供一个月...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.